FDA approves Cuvrior for treatment of adults with stable Wilson’s disease

Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine, according to a company press release.Cuvrior (trientine tetrahydrochloride, Orphalan) recently demonstrated noninferiority to penicillamine by measurement of non-ceruloplasmin copper in a global, phase 3 trial; penicillamine is currently approved as a first-line treatment for Wilson’s with approximately one-third of patients developing intolerance.“As a physician, I have seen firsthand how Wilson’s disease impacts theRead More